J&J/Novartis fined over EU fentanyl pay-for-delay deal
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and Novartis have been fined a total of more than €16m by the European Commission for delaying the marketing of a cheaper generic version of the painkiller fentanyl in the Netherlands in contravention of EU competition law. Fentanyl is used mainly for pain in cancer patients.